🇺🇸 FDA
Pipeline program

Lasofoxifene

A2181042

Phase 2 small_molecule completed

Quick answer

Lasofoxifene for Bone Loss is a Phase 2 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
LIGAND PHARMACEUTICALS INC
Indication
Bone Loss
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials